



Making Medicines Affordable

PRESS RELEASE

London, 3 April 2014

THE EUROPEAN BIOSIMILARS GROUP CALLS UPON NATIONAL AUTHORITIES AND MEDICAL SOCIETIES TO ACTIVELY ENGAGE IN REDUCING THE KNOWLEDGE GAP ABOUT BIOSIMILAR MEDICINES

Around 250 delegates from 34 countries, including 63 authorities and academics, have joined the 12th EGA International Biosimilar Medicines Conference, organised by the European Biosimilars Group (EBG), EGA Sector Group, to discuss the challenges and the opportunities that biosimilar medicines provide for patients and society at large.

Adrian van den Hoven, EGA Director General, in his welcome address, invited the delegates to put forward ideas and solutions which could be taken up in the months and years to come to bridge the information gap on biosimilars. Despite the fact that biosimilars have generated up until now around 300 million patient days of real world clinical experience¹, the information gap remains the main challenge. The EBG therefore calls upon European regulators and European Medical Societies to take an active role in informing the respective stakeholders about the stringent regulatory requirements that are in place to guarantee the safety, the quality and efficacy of all biologicals that are approved for marketing in Europe.

He also took the opportunity to share the EBG vision, which is to provide all patients in Europe with access to biological treatment options, thereby supporting the sustainability of the healthcare system and contributing to a healthier European society. This vision is built on 5 important pillars, being the essential elements of our contribution to society: patients, quality, value, sustainability and partnership.

Adrian van den Hoven concluded “We expect that policy makers recognise this value that we bring to society and engage with us in a partnership that will provide the regulatory predictability and stability that is needed to transform Europe into a hub for the production of biosimilars and also a fairer society that provides equal access to medicines for all patients”.

¹ Periodic Safety Update Reports (PSURs)